– USA, MA – Theseus Pharmaceuticals, Inc. (NASDAQ: THRX), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced the appointment of Dr. Steve Stein (M.D.) to its Board of Directors.
“We are delighted to welcome Dr. Stein to the Theseus Board as we advance development of our THE-630 and THE-349 programs, while also expanding our early-stage pipeline. Dr. Stein’s depth and breadth of oncology expertise, and extensive track record of bringing effective medicines through development and to patients, will be invaluable as we continue to build Theseus as a leading precision oncology company,” said CEO, Dr. Tim Clackson.
About Dr. Steven Stein
Dr. Stein currently serves as EVP, and CMO of the global biopharmaceutical company, Incyte, where he develops a strategy for Incyte’s therapeutic candidates and oversees verticals including clinical development, regulatory affairs, and medical affairs. Previously, he worked at Novartis Pharmaceuticals Corporation, where he most recently served as SVP, of U.S. Clinical Development & Medical Affairs at Novartis Oncology. Dr. Stein previously worked at GSK (formerly GlaxoSmithKline) as VP, of Global Oncology, Clinical Development and as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein was previously an assistant professor in the Department of Medicine at the University of Pennsylvania, where he had also completed a fellowship in hematology and oncology. Dr. Stein has served as a Kura Oncology’s Board of Directors member since January 2017.
He earned his medical degree from the University of Witwatersrand in Johannesburg, South Africa.
Dr. Stein said, “Theseus is backed by a foundation of success in targeted oncology, and I look forward to contributing to their continued growth and development through the Company’s near-term clinical milestones, and onward through the complex clinical and regulatory pathways that influence development in the targeted oncology space.”
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus’ lead product candidate, THE-630, is a pan-variant KIT inhibitor for treating patients with advanced gastrointestinal stromal tumors, whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing THE-349, a fourth-generation, selective epidermal growth factor receptor inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in non-small cell lung cancer patients.
For more information: https://theseusrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.